• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Bausch + Lomb Corporation Common Shares (NY:BLCO)

    12.06 +0.21 (+1.77%)
    Official Closing Price Updated: 7:00 PM EDT, Apr 17, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Bausch + Lomb Corporation Common Shares

    < Previous 1 2 3 4 Next >
    3 Reasons to Sell BLCO and 1 Stock to Buy Instead
    Bausch + Lomb has gotten torched over the last six months - since October 2024, its stock price has dropped 41.5% to $12.06 per share. This might have investors contemplating their next move. 
    Via StockStory
    Topics Bankruptcy
    Exposures Financial Legal
    3 of Wall Street’s Favorite Stocks in the Doghouse
    Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
    Via StockStory
    Topics Firearms
    Exposures Firearms
    Q4 Earnings Roundup: Bausch + Lomb (NYSE:BLCO) And The Rest Of The Medical Devices & Supplies - Specialty Segment
    Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Bausch + Lomb (NYSE:BLCO) and its peers. 
    Via StockStory
    Q4 Earnings Highs And Lows: Haemonetics (NYSE:HAE) Vs The Rest Of The Medical Devices & Supplies - Specialty Stocks
    Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Haemonetics (NYSE:HAE) and the best and... 
    Via StockStory
    Earnings Scheduled For February 19, 2025
    Via Benzinga
    Why Bausch + Lomb Rallied Today
    The highly indebted healthcare stock rose on rumors it may be selling itself. 
    Via The Motley Fool
    Why Bausch + Lomb (BLCO) Shares Are Plunging Today
    Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 6.7% in the morning session after Wells Fargo downgraded the stock's rating from Buy to Hold. The firm cited concerns related to the "voluntary... 
    Via StockStory
    Topics Artificial Intelligence Initial Public Offering
    Exposures Artificial Intelligence Securities Market
    Tesla To $345? Here Are 10 Top Analyst Forecasts For Friday
    Via Benzinga
    Why Bausch + Lomb (BLCO) Stock Is Nosediving
    Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 10.6% in the afternoon session after the company announced the voluntary recall of intraocular lenses on its enVista platform. The recall was... 
    Via StockStory
    Topics Artificial Intelligence Initial Public Offering
    Exposures Artificial Intelligence Securities Market
    3 Healthcare Stocks in the Doghouse
    Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
    Via StockStory
    Topics Stocks
    Exposures COVID-19 US Equities
    Medical Devices & Supplies - Specialty Stocks Q4 In Review: Globus Medical (NYSE:GMED) Vs Peers
    Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Globus Medical (NYSE:GMED) and its peers. 
    Via StockStory
    3 Stocks Under $50 Walking a Fine Line
    Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and... 
    Via StockStory
    Bausch Health Stock Pops After-Hours On Q4 Earnings Beat, Bullish Outlook: Retail Confidence Rises
    The company’s Solta segment, which includes medical aesthetics, saw Q4 revenue climb 34% to $138 million, fueled by strong demand in South Korea and China. 
    Via Stocktwits
    Topics Earnings
    Exposures Financial
    Globus Medical (GMED) Q4 Earnings: What To Expect
    Medical device company Globus Medical (NYSE:GMED) will be announcing earnings results tomorrow after the bell. Here’s what to expect. 
    Via StockStory
    Earnings To Watch: Integer Holdings (ITGR) Reports Q4 Results Tomorrow
    Medical technology company Integer Holdings (NYSE:ITGR) will be announcing earnings results tomorrow before market hours. Here’s what you need to know. 
    Via StockStory
    Bausch + Lomb’s (NYSE:BLCO) Q4: Beats On Revenue
    Eyecare company Bausch + Lomb (NYSE:BLCO) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 9.1% year on year to $1.28 billion. On the other hand, the company’s full-year... 
    Via StockStory
    Bausch + Lomb (BLCO) Reports Earnings Tomorrow: What To Expect
    Eyecare company Bausch + Lomb (NYSE:BLCO) will be announcing earnings results tomorrow morning. Here’s what to expect. 
    Via StockStory
    Deal Dispatch: PharmChem Forgoes Banker To Run Sale, TGI Fridays Sells 19 Restaurants For $3.1 Million
    Bausch + Lomb's efforts to sell have so far been unsuccessful. Meanwhile, KKR is aggressively pursuing a deal for Fuji Soft. 
    Via Benzinga
    Aehr Test Systems Posts Weak Results, Joins Trump Media & Technology Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
    Via Benzinga
    Topics Government
    Exposures Political
    Macy's, Dave & Buster's, Bausch + Lomb And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
    Via Benzinga
    Deal Dispatch: Ubisoft In Buyout Talks, Dental Supplier Explores Sale, Beloved Drive-Through Goes Bankrupt
    Dental supply maker Patterson Companies Inc announced Thursday that it is exploring strategic options, including a sale or merger, to boost shareholder value. 
    Via Benzinga
    Topics Supply Chain
    Exposures Supply Chain
    Deal Dispatch: UFC, WWE Parent TKO Takes On Bull Riding; Endeavor Looks To Sell Tennis; Another Car Company Goes Bankrupt
    IMG tennis assets are on the auction block. The announcement came after TKO inked a deal with Endeavor for Professional Bull Riders. 
    Via Benzinga
    Deal Dispatch: Altus Power, Motorsport Games Explore Options, True Value Goes Bankrupt, M&A Activity Lags
    S&P Global's Joe Mantone puts the latest M&A data in perspective and how deal pros might react post-Election Day. 
    Via Benzinga
    Topics Bankruptcy Stocks
    Exposures Financial Legal US Equities
    This Advance Auto Parts Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
    Via Benzinga
    Why Bausch + Lomb Stock Soared by Over 7% on Monday
    It was quite a busy and eventful day for the company. 
    Via The Motley Fool
    NVIDIA, Trump Media & Technology, Bausch + Lomb, Sirius XM And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Topics Government
    Exposures Political
    Bausch + Lomb Sale Process Gains Momentum As TPG And Blackstone Join Forces
    Private equity giants TPG and Blackstone are pursuing a potential $14 billion buyout of Bausch + Lomb. 
    Via Benzinga
    Nike Reports Weak Sales, Joins Lamb Weston And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
    Via Benzinga
    Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
    Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap stocks last week. 
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Applied Therapeutics, PowerFleet, VF Corp, Victoria's Secret And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.